

## Original Article

# Mixed micelles loaded with silybin-polyene phosphatidylcholine complex improve drug solubility

Rui-ling DUAN, Xun SUN, Jie LIU, Tao GONG\*, Zhi-rong ZHANG\*

Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu 610041, China

**Aim:** To prepare a novel formulation of phosphatidylcholine (PC)-bile salts (BS)-mixed micelles (MMs) loaded with silybin (SLB)-PC complex for parenteral applications.

**Methods:** SLB-PC-BS-MMs were prepared using the co-precipitation method. Differential scanning calorimetry (DSC) analysis was used to confirm the formation of the complex and several parameters were optimized to obtain a high quality formulation. The water-solubility, drug loading, particle size, zeta potential, morphology and *in vivo* properties of the SLB-PC-BS-MMs were determined.

**Results:** The solubility of SLB in water was increased from  $40.83 \pm 1.18$   $\mu\text{g}/\text{mL}$  to  $10.14 \pm 0.36$   $\text{mg}/\text{mL}$  with a high drug loading (DL) of  $14.43 \pm 0.44\%$  under optimized conditions. The SLB-PC-BS-MMs were observed by transmission electron microscopy (TEM) and scanning electron microscopy (SEM) and showed spherical shapes. The particle size and zeta potential, as measured by photon correlation spectroscopy (PCS), were about  $30 \pm 4.8$  nm and  $-39 \pm 5.0$  mV, respectively. *In vivo* studies showed that incorporation of the SLB-PC complex into PC-BS-MMs led to a prolonged circulation time of the drug.

**Conclusion:** This novel formulation appears to be a good candidate for drug substances that exhibit poor solubility for parenteral administration.

**Keywords:** silybin; bile salts; phospholipid complex; mixed micelles; solubility

Acta Pharmacologica Sinica (2011) 32: 108–115; doi: 10.1038/aps.2010.192; published online 20 Dec 2010

## Introduction

The solubility of active pharmaceutical ingredients (APIs) has always been a concern for formulations because inadequate aqueous solubility may hamper the development of parenteral products and limit their bioavailability<sup>[1]</sup>. To solve this problem, several approaches have emerged to improve API solubility, such as salt formation<sup>[2]</sup>, crystal engineering<sup>[3]</sup>, nano-sizing<sup>[4]</sup>, lipid formulation<sup>[5]</sup>, cyclodextrin complexation<sup>[6]</sup> and prodrug strategies<sup>[7]</sup>. Among these, we focused on the mixed micelle systems due to their synergistic properties, such as increased micelle stability and drug loading efficiency, which are superior to those of the individual components<sup>[8]</sup>.

In the current study, we selected silybin (SLB) as the model drug to validate the feasibility of mixed micelle systems. Silybin, a flavolignan that represents approximately 60%–70% of silymarin, is an antioxidant isolated from the fruits of milk thistle, *Silybum marianum* Gaertn. Interest in this agent has

grown in recent years due to its wide array of beneficial pharmacological effects, including antioxidative, anti-lipid-peroxidative, antifibrotic, anti-inflammatory, immunomodulating and even liver regenerating effects<sup>[9–11]</sup>.

Despite the promising biological effects of SLB, its poor water solubility (about 40  $\mu\text{g}/\text{mL}$ ) and oral bioavailability (about 0.73%) in both rodents and humans, as reported by several researchers<sup>[12–15]</sup>, has restricted its clinical application. To improve this situation, there have been many contributions to the development of SLB formulations<sup>[15–17]</sup>. However, few have produced a marked effect, and a majority of them are based on oral drug delivery systems. Because no proper formulation of silybin has been approved for intravenous administration, our goal was to develop a novel mixed micelle system for its parenteral application that could dramatically improve its solubility.

Upon consideration of its physiological compatibility and solubilizing capacity, the phosphatidylcholine-bile salts-mixed micelle system (PC-BS-MM) seems to be a good candidate for intravenous drug administration<sup>[18, 19]</sup>. Bile salts (BS), detergent-like chemicals produced by the liver and stored in the gall bladder, are able to solubilize phosphatidylcholine

\* To whom correspondence should be addressed.

E-mail gongtaoy@126.com (Tao GONG);

zrzzi@vip.sina.com (Zhi-rong ZHANG)

Received 2010-06-20 Accepted 2010-10-12

(PC) to a large extent, forming a clear mixed micellar solution that is able to solubilize substances with poor water solubility<sup>[20]</sup>. Previous studies have shown that the hemolytic effect of bile salts can be neutralized by solubilized phospholipids<sup>[21]</sup>. In addition, PC-BS-MMs can be locally and systemically tolerated with no embryotoxic, teratogenic or mutagenic effects<sup>[22]</sup>. Therefore, these PC-BS-MMs might be the ideal drug carrier of SLB for parenteral administration.

Despite the encouraging potential applications of PC-BS-MMs mentioned above, preparing formulations of SLB with poor solubility enveloped in these carriers remains a challenge. Thus, it is expected that the SLB-PC complex, with changed solubility, would be better incorporated into PC-BS-MMs.

To examine the potential of our model (PC-BS-MMs) as a novel delivery vehicle for water-insoluble drugs, the specific objectives of this work were (i) to formulate an SLB-PC complex in PC-BS-MMs for parenteral application by screening different formulation factors, (ii) to investigate the characteristics of the optimized SLB-PC-BS-MM formulation and (iii) to compare the pharmacokinetic parameters *in vivo* between the SLB-PC-BS-MMs and silybin-*N*-methylglucamine.

## Materials and methods

Silybin (SLB) was purchased from Xi'an Sino-herb Bio-technology Co Ltd (Xi'an, china), purity 98.32%. Polyene Phosphatidylcholine (PPC) was obtained from Lipoid GmbH (Germany), purity 94%. Sodium deoxycholate (SDC) was supplied by Beijing Aoboxing Biotechnologies Co Ltd (Beijing, China). The other chemical reagents were of analytical grade or better.

Male Wistar rats were provided by the West China Experimental Animal Center of Sichuan University (China). The protocol was approved by the Institutional Animal Care and Use Committee of Sichuan University.

### Preparation of SLB-PPC complex

The preparation of SLB-PPC complex was carried out as previously described<sup>[15]</sup> with slight modifications. The complex was prepared with SLB and PPC at a molar ratio of 1:1. Weighed amounts of SLB and PPC were placed in a round bottom flask and dissolved in acetone. The mixture was then refluxed at 50 °C for 2 h. After the acetone was evaporated off under vacuum (Büchi, R-144 rotary evaporator, Switzerland), the dried residues were collected and placed in desiccators.

### Structure validation of SLB-PPC complex by differential scanning calorimetry (DSC)

DSC was performed on an EXSTAR 6000 thermogravimetric analyzer (EIKO, Japan), and a scan speed of 5 °C from 0 to 250 °C was employed. DSC thermograms of SLB, PPC, a physical mixture of SLB and PPC, and the SLB-PPC complex were compared to identify formation of the complex.

### Preparation of PPC-BS-MMs loaded with the SLB-PPC complex (SLB-PPC-BS-MMs)

Because the SLB-PPC complex exhibited good solubility in

anhydrous ethanol, the complex was easily loaded into PPC-BS-MMs using the co-precipitation method<sup>[23]</sup>. In brief, the complex, PPC and sodium deoxycholate (SDC) at certain molar ratios were dissolved in anhydrous ethanol. A film was formed after evaporation of the organic solvent at 50 °C. The resulting films were dispersed in double distilled water. To remove unsolubilized drug, the solutions were centrifuged at 16 000×g (Allegra X-22R Centrifuge, F2402H rotor, Beckman Coulter Inc, CA, USA) for 10 min. The supernatant contained the freshly formed mixed micelles. To increase the stability of the MMs, they were pre-frozen at -40 °C for at least 4 h and then lyophilized under a vacuum for 24 h.

### Determination of drug solubility and drug loading (DL%) in different micelle systems

The content of the SLB solubilized by MMs was determined by reverse-phase HPLC. SLB-PPC-SDC-MMs were diluted with methanol to a certain concentration and injected into an HPLC system. The stationary phase, a Kromasil C18 column (150 mm×4.6 mm, 5 μm), was kept at 35 °C. The mobile phase consisted of a mixture of acetonitrile and double distilled water (35:65) [pH adjusted to 3-4 using 10% phosphoric acid (*v/v*)]. The injection volume of the samples and standards was 20 μL. The flow rate was 1.0 mL/min and the detection wavelength was 288 nm.

The drug loading (DL%) was calculated as follows:

$$DL\% = \frac{\text{Amount of drug in prescription}}{\text{Amount of drug added} + \text{Amount of excipient added}} \times 100\% \quad (1)$$

### Determination of particle size and Zeta potential of SLB-PPC-SDC-MMs

After suspending the freeze-dried SLB-PPC-SDC-MMs in double distilled water, photon correlation spectroscopy (PCS) (Malvern Zetasizer Nano ZS90, Malvern instruments Ltd, UK) was used to measure the particle size and zeta potential of the MMs. Each sample was then analyzed in triplicate.

### Morphology of SLB-PPC-SDC-MMs determined by scanning electron microscopy (SEM) and transmission electron microscopy (TEM)

One drop of the diluted SLB-PPC-SDC-MMs was placed on a graphite surface. After being oven-dried, the sample was coated with gold using an ion sputter and examined with a conventional scanning electron microscope (JSM-5900LV, JEOL, Japan).

Before analysis by transmission electron microscopy, diluted samples were placed on copper grids with films and then stained with 2% (*w/v*) phosphotungstic acid; the excess staining solution was removed with filter paper. After being air dried, the films were observed with a transmission electron microscope (H-600, Hitachi, Japan).

### *In vivo* studies in rats

Ten rats (200±20 g) were divided into 2 groups at random.

Silybin-*N*-methylglucamine solution or SLB-PPC-SDC-MMs (corresponding to a dose of 80 mg/kg) was injected into the tail vein of the rats of each group, respectively. After administration, blood was collected from the end of the tail at specific time points. Blood was immediately processed for plasma by centrifugation at 1500×*g* for 10 min. The obtained plasma was stored at -20 °C until analysis.

The plasma samples were prepared as follows to determine the SLB. One hundred microliters of internal standard (andrographolide: 200 µg/mL) and 100 µL of 0.1 mol/L phosphate buffer (pH 8.0) were added to 100 µL of plasma, followed by agitation for 30 s. Then, 2.5 mL of absolute ether was added, and this mixture was shaken for 15 min and then centrifuged at 1500×*g* for 5 min. Two milliliters of the organic phase was quantitatively transferred into clear centrifuging tubes and evaporated under nitrogen at 40 °C. The residues were resuspended in 100 µL of methanol and centrifuged at 9200×*g* for 10 min. Next, 20 µL of the supernatant was injected for HPLC analysis. The HPLC conditions were the same as the determination of drug solubility.

### Statistical analysis


The results were analyzed by Drug and Statistics (DAS) software. Significance was tested by a two-tailed *t*-test and a value of  $P < 0.05$  was considered statistically significant.

## Results

### Structure identification of SLB-PPC complex by DSC

Differential scanning calorimetry (DSC) is a fast and reliable method to identify the formation of phospholipid complexes<sup>[15, 24]</sup>. Figure 1 shows the DSC thermograms of pure silybin (SLB), polyene phosphatidylcholine (PPC), the SLB-PPC complex and a physical mixture of SLB and PPC.

The melting point of SLB was 136.5 °C. The DSC profile of



**Figure 1.** DSC thermograms of SLB, PPC, the SLB-PPC complex and a physical mixture of SLB and PPC.


PPC showed two different types of endothermal peaks. The first mild endothermal peak at approximately 109.4 °C was probably due to movement of the polar regions of the PPC molecule. The second endothermal peak at 232.1 °C was very sharp, and its appearance was likely due to a phase transition from a gel to a liquid crystalline state. The non-polar hydrocarbon tail of PPC may melt during this phase, yielding a sharp peak.

The thermogram of a physical mixture of SLB and PPC was almost the overlap of each individual component, except for some slight differences. Specifically, the peak at 135.9 °C, which should be the melting point of SLB, was a little lower than that of pure SLB. The second peak of PPC disappeared, indicating that the PPC melted and the drug dissolved in the PPC at higher temperature. It is likely that a SLB-PPC complex was partially formed.

The thermogram of the SLB-PPC complex showed that the endothermal peaks of SLB and PPC had almost disappeared with the exception of a small peak at 236.9 °C, which was probably due to a very small amount of unreacted PPC. Two more new peaks at 92.0 and 194.6 °C were present, indicating the formation of a SLB-PPC complex. The peak at 92.0 °C was attributed to interactions of the polar groups of SLB and PPC in the form of hydrogen bonds, which occur through the -OH groups of the phenol rings of SLB<sup>[15, 24]</sup>. Such interactions are supposed to be the dominant factor in the complexation process, as the peak at 92.0 °C in the DSC curve absorbed more energy than the others. The peak at 194.6 °C, which absorbed less energy, might be associated with the changed spatial structure of the hydrocarbon chains.

### Determination of drug solubility and drug loading (DL%) in different micelle systems


The influence of the SDC concentration on SLB solubility in the mixed micelles and the drug loading efficiency is shown in Figure 2. Upon increasing the SDC concentration from 8 to 40 mg/mL, a significant increase in SLB solubility was observed, but a further increase in SDC concentration led to saturation. As for the drug loading efficiency, an enhanced SDC concentration (from 8 to 20 mg/mL) led to an increased drug loading of up to 14.43%. However, a continuous increase in SDC



**Figure 2.** Influence of the SDC concentration on SLB solubility and drug loading at 10 °C (PPC conc, 40 mg/mL) ( $n=3$ ).


concentration did not improve the solubilization efficiency. Therefore, an SDC concentration of 20 mg/mL, at which concentration the PPC-SDC molar ratio was 1 and solubilized silybin could be up to  $10.14 \pm 0.36$  mg/mL, was adopted for further investigations.

The influence of the PPC concentration on SLB solubility and drug loading efficiency was also investigated. As shown in Figure 3, SLB solubility was enhanced by incorporating increasing amounts of PPC in the MM system. After reaching a concentration of 60 mg/mL, continuously increasing the PPC concentration resulted in a relatively stable solubilization of SLB and eventually decreased solubility. However, a further increase in the PPC amount (after 40 mg/mL) led to a dramatic decrease in drug loading efficiency. Hence, to ensure higher solubilization efficiency and lower viscosity, a PPC concentration of 40 mg/mL was chosen for further investigations. At this concentration, the PPC-SDC molar ratio was 1, which agrees with the results regarding the influence of the SDC concentration.



**Figure 3.** Influence of total PPC concentration on SLB solubility and drug loading at 10 °C (SDC conc, 20 mg/mL) ( $n=3$ ).

The effect of the pH value on the solubility of SLB in PPC-SDC-MMs is shown in Figure 4. The results showed that enhancing the pH value of the mixed micellar solvent can dramatically increase the solubility of SLB when the pH is between 2 and 8. However, SLB was not stable at pH val-



**Figure 4.** Effect of pH on SLB solubility in PPC-SDC-MMs at 10 °C (PPC/SDC molar ratio=1; PPC conc 40 mg/mL; dispersion medium: 0.05 mol/L phosphate buffer) ( $n=3$ ).

ues above 9 or even 8. Hence, the optimum condition was between pH 7 and 8, which was exactly the pH value of the mixed micelles. Therefore, it was not necessary to use an additional pH regulator in this delivery system.


Other factors that affect the solubility of mixed micelles, such as ionic strength and temperature, were investigated, and the results are shown in Table 1. A rapid decrease in the solubility of silybin occurred with increasing ionic strength and temperature. Therefore, a low ionic strength and temperature are recommended for the preparation of SLB-PPC-SDC-MMs.

**Table 1.** Effect of ionic strength and temperature on silybin solubility in PPC-SDC-MMs (PPC/SDC molar ratio=1; PPC conc 40mg/mL) ( $n=3$ ).

Temperature (°C)	Dispersion medium	SLB solubility (mg/mL)
10	Water	$10.34 \pm 0.29$
10	Phosphate buffer, pH 7.4, 25 mmol/L	$8.73 \pm 0.37$
10	Phosphate buffer, pH 7.4, 50 mmol/L	$6.46 \pm 0.31$
25	Water	$9.57 \pm 0.24$
40	Water	$8.22 \pm 0.25$

#### Particle size and morphology of SLB-PPC-SDC-MMs


SLB-PPC-SDC-MMs were characterized by PCS and exhibited an average diameter of  $(30.7 \pm 4.8)$  nm. SEM and TEM images of SLB-PPC-SDC-MMs are presented in Figures 5 and 6, respectively. Both techniques confirmed that the mixed micelles were spherical in shape with a diameter of about 30 nm.



**Figure 5.** Scanning electron micrographs of SLB-PPC-SDC-MMs at  $\times 40\,000$  magnification; scale bar: 500 nm.

#### Zeta potential

Zeta potential is an important factor in evaluating the stability of a colloidal dispersion<sup>[25]</sup>. Generally speaking, the particles were stable when the absolute value of the zeta potential was above 30 mV due to the electric repulsion between particles<sup>[26-28]</sup>. The average zeta potential of the SLB-PPC-SDC-MMs was  $(-39 \pm 5.0)$  mV, which suggests that the MMs obtained in this study could be a dynamic stable system.




**Figure 6.** Transmission electron micrographs of SLB-PPC-SDC-MMs at  $\times 60\,000$  magnification; scale bar: 100 nm.

### In vivo studies in rats


As seen in Figure 7, the internal standard (andrographolide) and silybin in plasma were completely separated under our analytical conditions, with retention time of 5 and 7 min, respectively. Figure 8 and Table 2 show the main pharmacokinetic parameters in rats after intravenous injection of silybin-*N*-methylglucamine or SLB-PPC-SDC-MMs (equivalent to 80 mg/kg of silybin), respectively ( $n=5$ ). From the profile, we could see the mean retention time (MRT) and  $AUC_{(0-\infty)}$  of the SLB-PPC-SDC-MMs group were 29.8 min and 2190 mg/L·min, respectively. In comparison, the MRT and  $AUC_{(0-\infty)}$  of the silybin-*N*-methylglucamine group were 14.8 min and 1517 mg/L·min, respectively, which were significantly lower ( $P<0.05$ ) than that of the SLB-PPC-SDC-MMs group. However, these two groups achieved approximately the same  $C_{max}$  value ( $P>0.05$ ). These results suggested the SLB-PPC-SDC-MMs could remain in circulation *in vivo* longer than silybin-*N*-methylglucamine, which results in a higher  $AUC_{(0-\infty)}$  (1.44-fold).

### Discussion

The phosphatidylcholine-bile salts-mixed micelle system has demonstrated great potential as a novel delivery vehicle for



**Figure 7.** Typical chromatograms of silybin. (A) Blank rat plasma; (B) Blank rat plasma spiked with internal standard (andrographolide) and silybin; (C) A sample after intravenous administration of the SLB-PPC-SDC-MMs.



**Figure 8.** Mean plasma concentration-time curve of silybin in rats after intravenous administration of silybin-*N*-methylglucamine and SLB-PPC-SDC-MMs ( $n=5$ ).

**Table 2.** The main pharmacokinetic parameters of silybin-*N*-methylglucamine and SLB-PPC-SDC-MMs in rats ( $n=5$ ).

Parameters	Silybin- <i>N</i> -methylglucamine	SLB-PPC-SDC-MMs	t-test
$AUC_{(0-t)}$ (mg/L·min)	1508 $\pm$ 131	2128 $\pm$ 234	$P<0.05$
$AUC_{(0-\infty)}$ (mg/L·min)	1517 $\pm$ 130	2191 $\pm$ 266	$P<0.05$
$t_{1/2}$ (min)	13.0 $\pm$ 0.83	36.1 $\pm$ 6.61	$P<0.05$
MRT <sub>(0-t)</sub> (min)	14.2 $\pm$ 0.18	25.0 $\pm$ 1.57	$P<0.05$
MRT <sub>(0-\infty)</sub> (min)	14.8 $\pm$ 0.11	29.8 $\pm$ 3.79	$P<0.05$
$C_{max}$ (mg/L)	74.6 $\pm$ 5.66	80.7 $\pm$ 6.47	$P>0.05$
Relative bioavailability (%)		144	

parenteral administration to overcome the obstacles of inadequate aqueous solubility and oral bioavailability. However, researchers are facing challenges associated with encapsulating drug substances that are neither lipophilic nor hydrophilic into such carriers. The development of a drug-phospholipid complex is expected to overcome this problem. In the current study, the complex greatly enhanced the lipophilicity of the drug substances, which proved to be well incorporated in the mixed micelles. Additionally, polyene phosphatidylcholine, the phospholipid we employed in the complexation process, has the same biological effect as SLB in maintaining liver health and treating liver disorders<sup>[29]</sup>. This suggests that the use of a SLB-PPC complex is a promising strategy for the systemic delivery of SLB.

In order to optimize the SLB-PPC-SDC-MM preparation, different process variables were evaluated, and the water-solubility and drug loading efficiency were employed as evaluation parameters. First, the influence of SDC concentration was investigated, and the results are shown in Figure 2. An increase of SDC concentration of up to 20 mg/mL resulted in a significant enhancement of drug solubility and drug loading efficiency. However, a further increase of SDC concentration led to dramatic reduction in drug loading efficiency, although SDC could still solubilize the drug to some extent. This underlying process accounts for achievement of the highest combination rate of SDC and PPC when the SDC concentration was

increased to 20 mg/mL. Although excess free SDC micelles could also solubilize SLB, the solubilizing capacity was weaker than that of the mixed micelles.

Another important factor in the SLB-PPC-SDC-MM formulation was PPC concentration. When the molar ratio of PPC/SDC was below 1.0 (PPC concentration at 40 mg/mL), the increase in solubility and drug loading efficiency of SLB was dramatic, which was due to the dual increase of both the size and the lipophilicity of PPC-SDC-MM upon the incorporation of PPC<sup>[19]</sup>. Continuously increasing the PPC concentration resulted in a relatively stable solubilization of SLB and a rapid decrease in drug loading efficiency. This was also because the strongest binding force between PPC and SDC was achieved, similar to the influence of the SDC concentration. In addition, an increase in the PPC concentration resulted in a higher viscosity and, consequently, less partition of the drug into the mixed micellar space.

As for the effect of pH on the solubility of SLB, the results showed that the optimum condition for the SLB-PPC-SDC-MMs was between pH 7 and 8. This could be attributed to the different surface charges of the mixed micelles under different conditions. The lipid carrier displayed a less negative zeta potential at pH 2 than pH 8 and led to aggregation and further precipitation of the mixed micelles at lower pH values, which resulted in less solubilization of SLB under these conditions. However, some interactions between silybin and phospholipids, such as the combination of hydrogen bonds or van der Waals forces<sup>[13, 30, 31]</sup>, may not be very stable in highly charged environments (above pH 8). Therefore, a moderate pH value of medium is recommended for the preparation of the SLB-PPC-SDC-MMs.

Other factors such as increased ionic strength and temperature resulted in a rapid decrease in the solubility of silybin. This may be due to an increased critical micelle concentration under those conditions. Consequently, fewer micelles were available for the solubilization process. These findings are in good agreement with previous reports<sup>[32, 33]</sup>.

After different parameters were screened to obtain the optimized formulation, some characteristics of the SLB-PPC-SDC-MMs were investigated, such as particle size, zeta potential and morphology. The results showed the particles were 30 nm, -39 mV and spherical in shape, indicating it was a dynamic, stable and uniform system. Hence, it was necessary to develop a schematic representation of the structure of this formulation.

As mentioned in the identification of the SLB-PPC complex by DSC, hydrogen bonding played a major role in SLB-PPC complexation<sup>[13-15, 31]</sup>; the -OH groups of the phenol rings of SLB were engaged in hydrogen bonding with the phospholipids. This indicated that it was the polar part of PPC that interacted with the silybin. The structure of the PC-BS-MMs, studied systematically by many researchers<sup>[19, 34]</sup>, is widely accepted to be a 'mixed disk model'<sup>[35]</sup>. In this model, the mixed micelle consists of a disk-like portion of a phospholipid bilayer surrounded at its perimeter by bile salt molecules, exposing their hydrophilic surfaces to the aqueous solvent

and their lipophilic surfaces to the hydrocarbon tails of the phospholipid molecules. However, our observations by SEM and TEM indicated that the SLB-PPC-SDC-MMs were spherical in shape, which may be due to the presence of the SLB-PPC complex. Therefore, based on our experimental results, a schematic representation of the structure of the SLB-PPC-SDC-MMs is presented in Figure 9. Silybin first combines with the polar head group of PPC, forming a SLB-PPC complex. Then, using the co-precipitation method, the hydrocarbon tails of the PPC bind to the hydrophobic surface of SDC, forming spheres and exposing the hydrophilic surfaces of SDC to contact with the aqueous solvent.




Figure 9. Schematic representation of the structure of the SLB-PPC-SDC-MMs.

To further understand the characteristics of the SLB-PPC-SDC-MMs *in vivo*, pharmacokinetic studies were also performed. The results showed that the SLB-PPC-SDC-MMs remained in circulation *in vivo* longer than silybin-*N*-methylglucamine, which resulted in a higher AUC. Theoretically, the increased MRT and AUC were attributed to interactions between the drug and PPC-SDC-MMs when the mixed micelles were above the CMC<sup>[36, 37]</sup> at the beginning of administration. These combined forces would prolong the release of SLB into the blood. However, once the mixed micelles were diluted below the critical micelle concentration, the entrapped drug would be released into circulation. At this time, the released SLB-PPC complex, with different lipophilicity and solubility behavior, would play a major role in enhancing the MRT and AUC of SLB *in vivo*. This assumption is also verified by other literature<sup>[15]</sup>, which found that oral administration of a SLB-phospholipid complex could greatly enhance the MRT and AUC of SLB. In conclusion, it was the PPC-SDC-MMs and SLB-PPC complex combined that influenced the behavior of SLB *in vivo*.

Therefore, the SLB-PPC complex could not only improve the lipophilicity of SLB to be better enveloped in the PPC-SDC-MMs, but also increase its circulation time *in vivo*. The mixed micelle system, which remarkably improved the solubility of the SLB-PPC complex in water, could be used as a formulation for intravenous administration. PPC-SDC-MMs have been

investigated for the oral administration of silybin<sup>[38]</sup>. Nevertheless, we encapsulated the SLB-PPC complex in this carrier for intravenous administration because the oral bioavailability of SLB in rats was estimated to only be 0.73%<sup>[12]</sup>. To maximize the drug efficacy, it was necessary to develop a delivery system that can directly distribute into each organ, thereby avoiding the absorption process. Therefore, the obtained SLB-PPC-SDC-MMs in the current study should provide a dramatic increase in bioavailability compared to oral administration.

## Conclusions

In this paper, we have shown that silybin, a poorly soluble behavior drug, can be successfully enveloped into PPC-SDC-MMs after the formation of an SLB-PPC complex. The novel formulation with optimized formulation parameters dramatically improved both the water-solubility and the mean retention time of the drug *in vivo*. As a result, a new pattern of mixed micelles loaded with a phospholipid complex was proposed. This novel strategy was believed to be attractive for the development of drug substances that exhibit poor solubility.

## Acknowledgements

Financial support of this research was provided by the National Science & Technology Major Project of China (grant No 2009ZX09310-002) and the National Natural Science Foundation of China (No 30873165).

The authors thank Zhi-xiang YUAN, San-jun SHI and Chang-tao LUAN for their help with these experiments.

## Author contribution

Zhi-rong ZHANG and Tao GONG designed the research; Rui-ling DUAN performed the research and wrote the paper; Xun SUN and Jie LIU revised the paper.

## References

- Dressman J, Reppas C. Drug solubility: how to measure it, how to improve it. *Adv Drug Deliver Rev* 2007; 59: 531–2.
- Serajuddin, Abu TM. Salt formation to improve drug solubility. *Adv Drug Deliver Rev* 2007; 59: 603–16.
- Blagden N, Matas M de, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. *Adv Drug Deliver Rev* 2007; 59: 617–30.
- Kesisoglou F, Panmai S, Wu Y. Nanosizing – Oral formulation development and biopharmaceutical evaluation. *Adv Drug Deliver Rev* 2007; 59: 631–44.
- Hauss DJ. Oral lipid-based formulations. *Adv Drug Deliver Rev* 2007; 59: 667–76.
- Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. *Adv Drug Deliver Rev* 2007; 59: 645–66.
- Stella VJ, Nti-Addae KW. Prodrug strategies to overcome poor water solubility. *Adv Drug Deliver Rev* 2007; 59: 677–94.
- Gao Y, Li LB, Zhai G. Preparation and characterization of Pluronic/TPGS mixed micelles for solubilization of camptothecin. *Colloid Surface B* 2008; 64: 194–9.
- Kvasnicka F, Biba B, Sevcik R, Voldrich M, Kratka J. Analysis of the active components of silymarin. *J Chromatogr A* 2003; 990: 239–45.
- Tedesco D, Tava A, Galletti S, Tameni M, Varisco G, Costa A, *et al*. Effects of silymarin, a natural hepatoprotector, in periparturient dairy cows. *J Dairy Sci* 2004; 87: 2239–47.
- Trappoliere M, Caligiuri A, Schmid M, Bertolani C, Failli P, Di Manzano C, *et al*. Silybin is a direct antifibrogenic and antiinflammatory agent: Cellular and molecular mechanisms. *Digest Liver Dis* 2008; 40: A127.
- Wu JW, Lin LC, Hung SC, Chi CW, Tsai TH. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. *J Pharmaceut Biomed* 2007; 45: 635–41.
- Lasonder E, Weringa WD. An NMR and DSC study of the interaction of phospholipids vesicles with some anti-inflammatory agents. *J Colloid Interf Sci* 1990; 139: 469–78.
- Morazzoni P, Magistretti MJ, Giachetti C, Zanolio G. Comparative bioavailability of silipide, a new flavanolignan complex, in rats. *Euro J Drug Metab Pharmacokinet* 1992; 17: 39–44.
- Xiao YY, Song YM, Chen ZP, Ping QN. The preparation of silybin - phospholipid complex and the study on its pharmacokinetics in rats. *Int J Pharm* 2006; 307: 77–82.
- Chen W, Xia H, Wu W. Optimized preparation of silymarin dripping pills by a central composite design-response surface method. *Chin Trad Herb Drug* 2005; 36: 679–83.
- Wu W, Wang Y, Que L. Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. *Eur J Pharm Biopharm* 2006; 63: 288–94.
- Alkan-Onyuksel H, Ramakrishnan S, Chai HB, Pezzuto JM. A mixed micellar formulation suitable for the parenteral administration of taxol. *Pharm Res* 1994; 11: 206–12.
- Hammad MA, Müller BW. Increasing drug solubility by of bile salt-phosphatidylcholine-based mixed micelles. *Eur J Pharm Biopharm* 1998; 46: 361–7.
- Hammad MA, Müller BW. Solubility and stability of tetrazepam in mixed micelles. *Eur J Pharm Sci* 1998; 7: 49–55.
- Steffen H. Prinzip Mischmizelle. Die Gallensäure-Lecithin-Mischmizellen als Trägersystem schwer wasserlösliche Wirkstoffe. *Roche Magazine* 1984; 20: 2–9.
- Teelmann K, Schläppi B, Schüpbach M, Kistler A. Preclinical safety evaluation of intravenously administered mixed micelles. *Arzneimittelforschung* 1984; 34: 1517–23.
- Schurtenberger P, Mazer N, Känzig W. Micellar vesicle transition in aqueous solution of bile salt and lecithin. *J Phys Chem* 1985; 89: 1042–9.
- Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. *Int J Pharm* 2007; 330: 155–63.
- Komatsu H, Kitajima A, Okada S. Pharmaceutical characterization of commercially available intravenous fat emulsions: estimation of average particle size, size distribution and surface potential using photon correlation spectroscopy. *Chem Pharm Bull* 1995; 43: 1412–5.
- Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. *Eur J Pharm Biopharm* 2000; 50: 161–77.
- Müller RH, Rühl D, Runge SA. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. *Int J Pharm* 1996; 144: 115–21.
- Liu J, Gong T, Wang CG, Zhong ZR, Zhang ZR. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: Preparation and characterization. *Int J Pharm* 2007; 340: 153–62.
- Horejsová M, Urban J. The effect of polyene phosphatidylcholine (Essentiale forte) in the treatment of liver steatosis and ultrasound findings—preliminary study. *Cas Lek Cesk* 1994; 133: 366–9.

- 30 Hwang SB, Shen TY. Membrane effects of anti-inflammatory agents. 2. Interaction of nonsteroidal anti-inflammatory drugs with liposome and purple membranes. *J Med Chem* 1981; 24: 1202-12.
- 31 Venema FR, Weringa WD. The interactions of phospholipid vesicles with some anti-inflammatory agents. *J Colloid Interf Sci* 1988; 125: 484-500.
- 32 Flockhart BD. The effect of temperature on the critical micelle concentration of some paraffin-chain salt. *J Colloid Sci* 1961; 16: 484-92.
- 33 Alkan-Onyuksel H, Son K. Mixed micelles as proliposomes for the solubilization of teniposide. *Pharm Res* 1992; 9: 1556-62.
- 34 Carey MC, Small DM. The characteristics of mixed micellar solutions with particular reference to bile. *Amer J Med* 1970; 49: 590-608.
- 35 Mazer NA, Benedek GB, Carey MC. Quasielastic light-scattering studies of aqueous biliary lipid systems. Mixed micelle formation in bile salt-lecithin solutions. *Biochem* 1980; 19: 601-15.
- 36 Dongowski G, Fritzsche B, Giessler J, Härtl A, Kuhlmann O, Neuber RHH. The influence of bile salts and mixed micelles on the pharmacokinetics of quinine in rabbits. *Eur J Pharm Biopharm* 2005; 60: 147-51.
- 37 Ploema FGJ, Tucker JJ, Crommelin DJA. The role of bile salts in the intestinal absorption of drugs. *Acta Pharm Technol* 1990; 36: 43-52.
- 38 Yu JN, Zhu Y, Wang L, Peng M, Tong SS, Cao X, *et al*. Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate/phospholipid-mixed micelles. *Acta Pharmacol Sin* 2010; 31: 759-64.